# The effectiveness of adjuvant radiotherapy after thymoma resection: a systematic review and meta-analysis

## TL;DR

This study finds that adding radiotherapy after thymoma surgery may improve survival rates, but more research is needed.

## Contribution

A meta-analysis of 23 studies shows that postoperative radiotherapy improves survival outcomes in thymoma patients.

## Key findings

- Patients receiving surgery + radiotherapy had better overall and disease-specific survival rates at multiple time points.
- No significant difference was found in disease-free survival at 3 years or disease-specific survival at 1 year.
- The results suggest a potential benefit of radiotherapy, though prospective studies are needed for confirmation.

## Abstract

Our systematic review and meta-analysis aimed to investigate the impact of postoperative radiotherapy(PORT) on patient outcomes following thymoma resection.

A comprehensive search of PubMed, EMbase, The Cochrane Library, Web of Science, Wanfang, Wipo, and China Knowledge Network databases was systematically conducted. Relevant literature comparing the therapeutic efficacy and effectiveness of thymectomy and thymectomy+ PORT in patients with thymoma published until August 2024 was gathered. The retrospective studies included in this analysis were evaluated using the Newcastle-Ottawa Scale (NOS), while meta-analysis of the literature was performed using Review Manager 5.4 software.

A total of 23 retrospective studies, encompassing 13,742 patients, were included in the analysis. Among them, 6,980 patients belonged to the surgery-only group (3,321 male patients and 3,659 female patients), with an average age of 54.08 years. The surgery + PORT group consisted of 6,762 patients (3,385 male patients and 3,377 female patients) with an average age of 53.76 years. All included studies had a NOS score of ≥7.The meta-analysis results revealed that, in comparison to the surgery group, the surgery + PORT group exhibited higher rates of overall survival at 1 year, 3 years, 5 years, and 10 years. Additionally, the surgery + PORT group demonstrated superior disease-free survival (DFS)rates at 1 year and 5 years as well as disease-specific survival (DSS) rates at 3 years, 5 years, and 10 years. However, no significant differences were observed between the two groups in terms of DFS at 3 years or DSS at 1 year.

Available retrospective evidence indicates an association between PORT and improved survival after thymoma resection, though prospective validation is warranted.

The online version contains supplementary material available at 10.1186/s12957-025-04127-z.